# AU-007

Source: https://onco.cc/drugs/au-007/  
OnCo record `au-007` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

AU-007 is a monoclonal antibody from Aulos Bioscience, Inc., in registered phase 2 trials for metastatic cancer, melanoma, non-small-cell lung cancer.

## Summary

AU-007 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Aulos Bioscience, Inc., in metastatic cancer, melanoma, non-small-cell lung cancer, small-cell lung cancer. A monoclonal antibody, as described in the registry record. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Code: AU-007
- Modality: Monoclonal antibody
- Mechanism: A monoclonal antibody, as described in the registry record.

## Sources

- ClinicalTrials.gov: trials of AU-007: https://clinicaltrials.gov/search?intr=AU-007

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- trials: [Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Ca](https://onco.cc/trials/nct05267626/)

---
JSON: https://onco.cc/api/v1/entities/au-007.json